Results 101 to 110 of about 181,836 (188)
Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.ABSTRACT Background and Aims In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy. Methods Eligible participants from ADHERE run‐in period
Jeffrey A. Allen +8 more
wiley +1 more source
Retrospective analysis of ocular myasthenia gravis patients in Kuwait
, 2012 The statistics of ocular myasthenia gravis is fairly well established in western literature. This study was aimed to examine the rates of conversion of ocular myasthenia to generalized myasthenia in Kuwait and their response to ...
Raed Behbehani; Ashref AlMoosa
core
, 1992 A disorder of neuromuscular transmission recognized clinically by varying muscle weakness which is characterized by worsening with fatigue.IC-E10dii-myasthenia ...
Jeffrey G. Odel, MD
core
Characteristics of Diagnostic Testing in Ocular Myasthenia Gravis
, 2014 Estimates of the sensitivity of diagnostic testing in ocular myasthenia gravis vary.
Crandall E. Peeler; Lina Nagia; Jaao Lemos; Christopher Glisson; Sunita Yedavally; David Kaufman; Eric Eggenberger; Wayne T. Cornblath
core
Demographics of ocular myasthenia gra
, 2014 Among patients with generalized myasthenia gravis (GMG), women are more likely than men to present during early adulthood, with men typically developing GMG after 50 years of age.
Elena Bitrian; Michael S. Lee; Mark J. Kupersmith; Friedrich Zimprich; Jason H. Peragallo; Thomas J. Whittaker; Beau B. Bruce
core
Ocular Myasthenia Gravis Thymectomy Cohort Study
, 2018 The benefit of thymectomy in reducing prednisone requirement, symptom severity, need for immunosuppression, and hospitalization in patients with seropositive generalized myasthenia has recently been established. It is unclear whether this benefit applies
Ali Hamedani; Maxwell Pistilli; Kenneth Shindler; Robert Avery; Madhura Tamhankar; Grant Liu
core
Ocular Myasthenia: How do I Treat?
, 2019 Myasthenia gravis is caused by pathogenic autoantibodies to the postsynaptic neuromuscular junction. Clinically, this may affect any of the skeletal muscles causing variable weakness, which worsens with continued muscle activity. Ocular myasthenia gravis
Michael S. Lee, MD
core
Over-diagnosis of Ocular Myasthenia: Clinical Profile and Predictive Factors
To determine the prevalence, predictive factors, and clinical profile of patients with overdiagnosis of myasthenia. Methodology We retrospectively reviewed records of patients seen at our institute from January 2020 to September 2023, with an initial ...
Ramesh Kekunnaya
core
Ocular Myasthenia Mimicking Third Nerve Palsy
, 2015 66 year old man with ptosis OS and diplopia, slow saccades and pattern of a third nerve palsy. He shows a Cogan\u27s lid twitch. Differential diagnosis is cavernous sinus lesion vs myasthenia.
Jacqueline Winterkorn, MD, PhD (1947-2015)
core
Ocular Motor Dysfunction in Ocular Myasthenia Gravis: Effects of Treatment
, 2005 The optimal treatment of the ophthalmoparesis associated with ocular myasthenia gravis (OMG) remains unknown. We evaluated the efficacy of prednisone and pyridostigmine in reducing diplopia and ocular motor dysfunction in patients with ...
Mark J. Kupersmith; Gui-shuang Ying
core